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Background: Canine pemphigus foliaceus is an autoimmune antibody-mediated skin disease characterized by
acantholysis. The objective of this case report is to present the successful management of steroid refractory
pemphigus foliaceus with cytotoxic T-lymphocyte antigen 4 (CTLA4)-overexpressing adipose tissue mesenchymal
stem cells (ATMSCs).
Case presentation: A 10-year-old, 12.3-kg, castrated male Shih Tzu presented with severe pruritus and anorexia.
The diagnosis of pemphigus foliaceus was made based on its history, physical examination, and histopathology
results of a skin biopsy. Treatment with prednisolone and combination therapy of other immunosuppressive drugs
had failed; therefore, immunosuppressive gene, CTLA4 overexpressing ATMSCs (CTLA4-ATMSCs) and/or naive
ATMSCs administration was performed with the consent of the owner. ATMSCs were administered 21 times over a
period of 20 months with intervals of 2 to 8 week. Prednisolone was gradually tapered concurrently and no relapse
of the clinical signs was observed. After the termination of CTLA4-ATMSCs and/or naive ATMSCs treatment, the skin
lesions had improved and could be managed with a low dose of prednisolone for 12 months.
Conclusion: CTLA4-ATMSCs or naive ATMSCs transplantation may be beneficial as adjunctive therapy to initiate
and maintain the remission of skin lesions caused by pemphigus foliaceus in veterinary medicine.
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Canine pemphigus foliaceus is an autoimmune antibody-
mediated skin disease characterized by acantholysis. The
pathogenesis involves the production of autoantibodies
against a target protein in the adhesion molecules of ker-
atinocytes [1]. Desmoglein I is the main antigen impli-
cated in pemphigus foliaceus in dogs and humans [2,3].
Binding of antibodies to adhesion molecules such as
Desmoglein I disrupts the intercellular cohesion of kera-
tinocytes. This results in acantholysis and the typical le-
sions seen in pemphigus, including formation of blisters* Correspondence: vet.cew@gmail.com; hyyoun@snu.ac.kr
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unless otherwise stated.and intra-epidermal pustules. The cause is usually un-
known. However, some cases are possibly drug-induced
[4] or a sequel to a chronic inflammatory skin disease
[5]. The most successful treatment for canine pemphigus
foliaceus is immunosuppression [6] with corticosteroids
or cyclosporine. In recent studies, however, side effects
of this treatment such as diarrhea, polyuria/polydipsia,
weight gain, and recurrent infections have been de-
scribed [7,8]. Moreover, it has been reported that only
53% of treated cases survive for more than 1 year after
initiation of treatment [8].
Mesenchymal stem cells (MSCs) have immunosup-
pressive properties and inhibit a variety of cell types that
mediate both the adaptive and the innate immune response
[9,10]. MSCs suppress CD4+ and CD8+ T lymphocytes
independently and appear to inhibit the differentiation of
and antibody production by B cells [11,12] as well as theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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addition, MSCs have the ability to modulate T-cell prolifer-
ation and function. Based on these abilities, MSCs have
been proposed as a therapeutic option in the treatment
of autoimmune diseases and related gene overexpression
shows an increased therapeutic effect in autoimmune dis-
eases [14]. In our previous study, we tested the supernatant
from adipose tissue-derived MSCs (ATMSCs) and cytotoxic
T-lymphocyte antigen 4 (CTLA4)-overexpressing ATMSCs
(CTLA4-ATMSCs) for suppressive effects on the prolifera-
tion of peripheral blood mononuclear cells (PBMCs)
from dogs with experimental autoimmune thyroiditis.
Addition of the supernatant from CTLA4-ATMSCs
suppressed the proliferation of PBMCs stimulated
with thyroglobulin (autoantigen), when compared to the
addition of supernatant from ATMSCs. Under the same
controlled conditions, CTLA4-ATMSCs showed a stron-
ger suppression than nontransduced ATMSCs on the
proliferation of the autoantigen [15]. Therefore, CTLA4,
which has an inhibitory effect on T-cells, was transduced
into ATMSCs to increase the immunosuppressive ability.
This case report describes the successful management
of steroid refractory pemphigus foliaceus with CTLA4-
ATMSCs and/or naive ATMSCs. The treatment resulted
in the remission of the clinical signs that could be man-
aged with a low dose of prednisolone. No recurrence
was observed for 12 months.
Case presentation
A 10-year-old, 12.3 kg, castrated male Shih Tzu was
referred to the Veterinary Medicine Teaching HospitalFigure 1 Initial physical examination. Erythema, papules, pustules, crusts
abdomen and inguinal area (C), and the dorsal region of the trunk (D).(VMTH) of Seoul National University with severe pru-
ritus and anorexia for the past 7 months. The dog had
been treated with prednisolone orally twice daily
(4.4 mg/kg/day) and systemic antibiotics after the diag-
nosis of pemphigus foliaceus was made at a local veter-
inary clinic. Despite the treatment, the waxing and
waning lesions worsened over time.
Physical examination revealed mild depression and
generalized crusting. Papules and pustules were seen on
the neck, elbows, ears, abdomen, perianal area, inguinal
area, axillae, and the dorsal part of the trunk. Alopecia
of the forelimbs was also evident (Figure 1). Skin scra-
pings were performed to exclude Demodex canis and
other ectoparasites. Cytology of an impression smear
from a pustule revealed neutrophils and acantholytic
keratinocytes. Bacterial and fungal infections had been
ruled out at the previous local veterinary clinic. The
blood profile (complete blood count and serum bioche-
mistry) showed leukocytosis [white blood cells (WBCs)
58100/μL] and mild anemia [packed cell volume (PCV)
27%]. Serum biochemistry revealed an elevation of liver
enzymes [alkaline phosphatase (ALP) 1828 U/L and
gamma glutamyl transferase (GGT) 22 U/L], most likely
caused by the long-term corticosteroid treatment. Due to
malnutrition, hypoproteinemia was also present [total pro-
tein (TP) 3.3 g/dL, albumin 2.2 g/dL].
The definitive diagnosis of pemphigus foliaceus was made
by histopathological examination of skin biopsies taken
from the lesions on the forelimbs. Histopathology revealed
a mixture of neutrophils, fibrin debris, and numerous
acantholytic keratinocytes. The dermal inflammation was, lichenification, and erosions on the neck (A), elbow and axilla (B),
Figure 2 Histopathology of a skin lesion. Superficial crusting composed of a mixture of neutrophils, fibrin debris, and numerous acantholytic
cells (A), acanthotic epidermis (B), perivascular, mild, mostly mastocytic and neutrophilic dermal inflammation (C), and characteristic acantholytic
cells. (H&E staining, magnification × 40, ×100, and × 200).
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The patient was treated with prednisolone (4 mg/kg/day,
orally twice daily) for immunosuppression, cephalexin
(60 mg/kg/day, orally twice daily) for controlling secondary
infections, and with liver protectant drugs (lefotil 1 T/day,
silymarin 20 mg/kg/day, and ursodeoxycholic acid 20 mg/
kg/day, orally twice daily). The symptoms initially improved
with a decrease in pruritus; however, recurred after one
month. Cyclosporine (5 mg/kg/day, orally once daily) and
azathioprine (2 mg/kg/day, orally once daily), were pre-
scribed adjunctively but did not improve the clinical signs.
Because none of the treatment had the desired effect,
ATMSCs injection therapy was decided with the consent
of owner. Stem cell therapies were carried out in the
Cell Therapy and Animal Cloning Clinic of VMTH with
the approval of College of Veterinary Medicine, Seoul
National University. Canine ATMSCs was provided by
K-STEMCELL Co. Ltd. (Seoul, Korea). To increase the
potency, the dog CTLA4 gene was transduced into canine
ATMSCs by lentiviral expression systems as described in a
previous study [15]. Canine ATMSCs and CTLA4 overex-
pressing ATMSCs (CTLA4-ATMSCs) positively expressed
CD29, CD44, and CD90, and did not express the surface
markers CD34 and CD45. The patient received CTLA4
ATMSCs (2 × 106 cells/kg) and/or ATMSCs (1 × 107 cells/Figure 3 Dosage changes of immunosuppressants after CTLA4 overex
treatment. The dose of prednisolone was gradually reduced and azathioprin
administration and arrows indicate the time of naive ATMSCs administration.kg) intravenously. Additional medicinal treatments, antibi-
otics (cephalexin 60 mg/kg/day, orally twice daily) and with
liver protectant drugs (lefotil 1 T/day, silymarin 20 mg/kg/
day, and ursodeoxycholic acid 20 mg/kg/day, orally twice
daily) were prescribed continually. After the first adminis-
tration of CTLA4-ATMSCs, the dog became less pruritic,
and the skin lesions improved. CTLA4-ATMSCs adminis-
tration was performed 6 times and naive ATMSCs adminis-
tration was performed 18 times over a period of 20 months
at intervals of 2 to 8 week. CTLA4-ATMSCs and naive
ATMSCs were concurrently transplanted at 4th, 5th and
6th administrations. During these 20 months, the dose of
prednisolone was gradually reduced and azathioprine was
discontinued (Figure 3). No recurrence of the skin lesions
was seen (Figure 4). After the termination of ATMSCs
treatment, the skin lesions were well managed with a low
dose of prednisolone (0.25 mg/kg/day, orally once daily).
Furthermore, the body weight increased and the blood pro-
file showed an improvement in the leukocytosis, anemia,
and liver enzyme elevation together with an improvement
in the body condition (Figure 5). The manageable state
lasted for 12 months after the last ATMSCs treatment.
Unfortunately, this dog died newly developed pulmonary
edema. At this time, skin lesions showed mild crusting
which were manageable with low dose prednisolone.pressing ATMSCs (CTLA4-ATMSCs) and/or naive ATMSCs
e was discontinued. Arrow heads indicate the time of CTLA4-ATMSCs
Figure 4 Physical examination after CTLA4 overexpressing ATMSCs (CTLA4-ATMSCs) and/or naive ATMSCs treatment. No lesions are
present on the neck (A), abdomen and inguinal area (B), and dorsal region of the trunk (C) after stem cell therapy.
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The most common lesions of pemphigus foliaceus are
scales, crusts, pustules, epidermal collarettes, erosions,
and erythema. Ulcerations are occasionally observed
indicating a deeper disease or secondary bacterial infec-
tion. In severe or chronic cases other observed signsFigure 5 Changes in body weight and blood profile after CTLA4 over
An increase in body weight (A) a reduction in number of leukocytes (B), a
a decrease in the liver enzyme concentration (E) are shown. Arrow heads i
the time of naive ATMSCs administration.include lymphadenopathy, edema, depression, fever, and
lameness when the footpads are involved [16]. The initial
skin lesions occur on the face and ears. The feet, claw
beds, footpads, and groin are commonly involved and
multifocal or generalized lesions develop within 6 months.
Waxing and waning of the condition is common [17].expressing ATMSCs (CTLA4-ATMSCs) and/or ATMSCs treatment.
n increase in the RBC count (C) and packed cell volume (PCV) (D) and
ndicate the time of CTLA4-ATMSCs administration and arrows indicate
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mune response against self-antigens. Immunosuppressive
therapy is an important element in the treatment of pem-
phigus foliaceus [18]. Common immunosuppressive medi-
cation includes corticosteroids, cyclosporine, azathioprine,
chlorambucil, cyclophosphamide and human immuno-
globulin. In addition, management of autoimmune skin
disease includes topical antimicrobial therapy and/or sys-
temic treatment. Symptomatic treatment with gentle kera-
tolytic shampoos such as chlorhexidine is often indicated
and antibacterial and anti-yeast therapy should be pre-
scribed where appropriate. These need to be continued
until the disease is under control.
Although pemphigus foliaceus is considered a manage-
able chronic disease, the reported survival rate after 1
year is only 53% [19] and 25% of the dogs do not show
complete remission with immunosuppressive therapy
[20]. Because of the high incidence of side effects of
corticosteroids and the large number of deaths within
the first year of treatment, combination treatment with
cyclosporine or azathioprine is suggested to decrease the
maintenance dose of corticosteroids [8]. Combination
therapy has improved clinical signs in some cases. How-
ever, cyclosporine absorption and clinical efficacy can
vary markedly among patients and some may not re-
spond to treatment despite attainment of target blood
cyclosporine concentrations [21]. In addition, it has been
reported that the combination of prednisolone with
azathioprine can cause gastric ulceration in dogs [22].
Therefore, alternative treatments are required to sub-
stitute the immunosuppressive drug.
MSCs are largely studied as a new therapeutic tool in
a number of clinical applications. Many studies indicate
that MSCs possess an immunosuppressive function [11]
that can be modulated by cytokines and toll-like recep-
tor ligands [23]. These immunosuppressive properties
have attractive therapeutic potential for treatment of
autoimmune diseases [24-27]. The poor immunogenicity
of MSCs demonstrated in vitro and in vivo favors the
use of allogeneic MSCs in clinical conditions. Overexpres-
sion of the CTLA4 gene can increase the immunosuppres-
sive properties of ATMSCs by lowering autoantibodies in
serum [15,25].
This case report describes the clinical application
of CTLA4-ATMSCs and/or naive ATMSCs in steroid
refractory pemphigus foliaceus. Initial treatment com-
prised immunosuppressive doses of prednisolone after
the diagnosis of pemphigus foliaceus. Treatment with
prednisolone alone did not have the desired effect and
combinations with cyclosporine and azathioprine were
prescribed, with no improvement in the clinical signs.
Side effects of the immunosuppression included melena
and anorexia and the skin condition deteriorated, with
lesions spreading over the whole body. After the firstadministration of CTLA4-ATMSCs, the skin lesions
improved. CLTA4-ATMSCs and/or naive ATMSCs were
administered 21 times over a period of 20 months with an
interval of 2 to 8 weeks. A tapering dose of prednisolone
was given concurrently. After termination of ATMSC
treatment, the skin lesions were well controlled with a
low dose of prednisolone and remained under control
for 12 months. To the best of our knowledge, this is
the first report describing the application of ATMSCs to
treat a canine autoimmune disease and manage clinical
remission. Although additional studies are needed to in-
vestigate the clinical application of CTLA4-ATMSCs or
naive ATMSCs further, in cases where several pharma-
ceutical trials have failed, CTLA4-ATMSCs or naive
ATMSCs transplantation could be considered as an ad-
junctive therapy.
Conclusion
CTLA4-ATMSCs or naive ATMSCs transplantation could
be beneficial as adjunctive therapy in both the remission
and management of lesions by canine pemphigus foliaceus
in veterinary medicine.
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